Operational revenue, meanwhile, grew 10 per cent YoY at Rs 105.8 crore. Net profit jumped 34 per cent to Rs 27.5 crore over the previous year quarter.
Thyrocare Technologies, however, announced that two centres of Nueclear Healthcare, the wholly owned subsidiary of their company, situated at Surat and Baroda have been closed due to unfair business practices by the Franchisee, it said in a separate regulatory filing. READ FILING HERE
is one of the leading pan-India diagnostic chains that conduct an array of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases. The diagnostics company is specializing in cost-effective pathological biochemical testing.
At 11:10 am, Thyrocare Technologies was trading 7 per cent higher at Rs 647 on the BSE. In comparison, the S&P BSE Sensex was up 1.8 per cent at 40,581 points. The trading volumes on the counter jumped over 10-fold with a combined 804,466 shares changing hands on the NSE and BSE till the time of writing of this report.